Jianping Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jianping Wu has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Qun Wang
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University
13 shared publications Ru Liu
Department of Neurology, Beijing Tiantan Hospital Capital Medical University Beijing China
12 shared publicationsQun Wang
Beijing Tiantan Hospital, Capital Medical University, Beijing, 10070, China
10 shared publicationsLei Sun
Beijing Tiantan Hospital, Capital Medical University
7 shared publicationsXi Guo
Beijing Tiantan Hospital, Capital Medical University, Beijing 10070, China; China National Clinical Research Center for Neurological Diseases, Beijing 10070, China; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 10070, China
7 shared publicationsAqeela Zahra
Department of Pharmacology, School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, 440070, China
6 shared publications
Latest Publications
- Open Access
- 18 October 2026
- Published by Wiley in Advanced Science
- p. e78329
Astrocyte‐Associated ABCA1/APOE Responses Accompany Hippocampal Lipid Remodeling and Ectopic Neuronal Accumulation During Epileptogenesis
Temporal lobe epilepsy (TLE) is characterized by progressive hippocampal remodeling, including reactive astrogliosis and aberrant neuronal positioning. Although lipid disturbances are implicated in epileptogenesis, how astrocyte‐associated lipid responses relate to hippocampal remodeling remains poorly understood. Here, human TLE and kainic acid (KA)‐treated mouse transcriptomic datasets identified ATP‐binding cassette transporter A1 (ABCA1)/Abca1 as a nominal astrocyte‐associated candidate, while KA‐ and pilocarpine‐induced status epilepticus (SE) elicited astrocyte‐associated ABCA1/apolipoprotein E (APOE) responses. Ectopic granule cells and immature neurons accumulated in the hilus and were spatially associated with ABCA1‐positive cells, including astrocytic profiles; perilipin 2 (PLIN2)‐positive puncta were nearby. Pretreatment with the retinoid X receptor (RXR) agonist bexarotene increased hippocampal ABCA1 expression, delayed severe KA‐induced behavioral seizure onset, and was associated with fewer chronic spontaneous seizures and reduced ectopic neuronal accumulation. Post‐SE bexarotene administration was associated with lower seizure frequency, ectopic neuronal accumulation, and astrocytic marker‐positive cell densities. Multi‐omic profiling identified bexarotene‐associated metabolic and lipidomic changes; transmission electron microscopy (TEM) showed a smaller mean hilar neuronal lipid‐droplet area per image, and protein analyses identified early changes in p38 and extracellular signal‐regulated kinase 1/2 (Erk1/2) phosphorylation. Together, these findings warrant further investigation of astrocyte‐associated lipid pathways as potential therapeutic targets in epilepsy‐associated hippocampal remodeling.
- 18 October 2026
- Published by Wiley in Advanced Science
- p. e78329
Open AccessAstrocyte‐Associated ABCA1/APOE Responses Accompany Hippocampal Lipid Remodeling and Ectopic Neuronal Accumulation During Epileptogenesis
Temporal lobe epilepsy (TLE) is characterized by progressive hippocampal remodeling, including reactive astrogliosis and aberrant neuronal positioning. Although lipid disturbances are implicated in epileptogenesis, how astrocyte‐associated lipid responses relate to hippocampal remodeling remains poorly understood. Here, human TLE and kainic acid (KA)‐treated mouse transcriptomic datasets identified ATP‐binding cassette transporter A1 (ABCA1)/Abca1 as a nominal astrocyte‐associated candidate, while KA‐ and pilocarpine‐induced status epilepticus (SE) elicited astrocyte‐associated ABCA1/apolipoprotein E (APOE) responses. Ectopic granule cells and immature neurons accumulated in the hilus and were spatially associated with ABCA1‐positive cells, including astrocytic profiles; perilipin 2 (PLIN2)‐positive puncta were nearby. Pretreatment with the retinoid X receptor (RXR) agonist bexarotene increased hippocampal ABCA1 expression, delayed severe KA‐induced behavioral seizure onset, and was associated with fewer chronic spontaneous seizures and reduced ectopic neuronal accumulation. Post‐SE bexarotene administration was associated with lower seizure frequency, ectopic neuronal accumulation, and astrocytic marker‐positive cell densities. Multi‐omic profiling identified bexarotene‐associated metabolic and lipidomic changes; transmission electron microscopy (TEM) showed a smaller mean hilar neuronal lipid‐droplet area per image, and protein analyses identified early changes in p38 and extracellular signal‐regulated kinase 1/2 (Erk1/2) phosphorylation. Together, these findings warrant further investigation of astrocyte‐associated lipid pathways as potential therapeutic targets in epilepsy‐associated hippocampal remodeling.
- Open Access
- 27 April 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (5) , 469
Mechanisms and Therapeutic Targets of Ischemia—Reperfusion Injury in Stroke: A Narrative Review Focusing on Blood—Brain Barrier Dysfunction
Ischemic stroke remains a leading cause of death and disability worldwide. While thrombolysis and endovascular thrombectomy are current mainstays of treatment, their clinical efficacy is often undermined by ischemia–reperfusion injury (I/R). This injury induces secondary brain damage, primarily via disruption of the blood–brain barrier (BBB). No approved therapies directly target BBB protection. This review reinterprets the pathophysiological mechanism of BBB disruption after stroke through a dynamic spatiotemporal framework. The pathological cascade reaction is clearly divided into two core stages: the ischemic phase is mainly driven by energy failure and calcium overload; the reperfusion phase is further divided into four consecutive and progressive sub-stages, namely, oxidative stress burst, amplification of inflammatory response, matrix metalloproteinase 9 (MMP-9)-mediated barrier degradation and programmed cell death. This review critically assesses current therapies and identifies major clinical translation gaps, including a temporal mismatch between preclinical and clinical windows, unacceptable toxicity, lack of durable efficacy and biphasic effects. Matching specific interventions to the different pathophysiological stages of blood–brain barrier disruption is essential for optimizing clinical outcomes.
- 27 April 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (5) , 469
Open AccessMechanisms and Therapeutic Targets of Ischemia—Reperfusion Injury in Stroke: A Narrative Review Focusing on Blood—Brain Barrier Dysfunction
Ischemic stroke remains a leading cause of death and disability worldwide. While thrombolysis and endovascular thrombectomy are current mainstays of treatment, their clinical efficacy is often undermined by ischemia–reperfusion injury (I/R). This injury induces secondary brain damage, primarily via disruption of the blood–brain barrier (BBB). No approved therapies directly target BBB protection. This review reinterprets the pathophysiological mechanism of BBB disruption after stroke through a dynamic spatiotemporal framework. The pathological cascade reaction is clearly divided into two core stages: the ischemic phase is mainly driven by energy failure and calcium overload; the reperfusion phase is further divided into four consecutive and progressive sub-stages, namely, oxidative stress burst, amplification of inflammatory response, matrix metalloproteinase 9 (MMP-9)-mediated barrier degradation and programmed cell death. This review critically assesses current therapies and identifies major clinical translation gaps, including a temporal mismatch between preclinical and clinical windows, unacceptable toxicity, lack of durable efficacy and biphasic effects. Matching specific interventions to the different pathophysiological stages of blood–brain barrier disruption is essential for optimizing clinical outcomes.
- Open Access
- 2 March 2026
- Published by Springer Nature in Acta Epileptologica
- Vol. 8 (1)
Unraveling the mechanisms of slack channel mutations in epileptic disorders
Sodium-activated potassium channels (K Na ) are extensively expressed throughout the central nervous system (CNS) and play a pivotal role in modulating neuronal excitability. The K Na achieve this by regulating the threshold for action potential initiation and the magnitude of post-hyperpolarization. The KCNT1 gene encodes the α subunit of K Na , also known as Slack channel, is crucial for governing the membrane excitability of neurons. Mutations in the KCNT1 gene impair the function of these potassium channels, leading to seizures and a spectrum of epileptic disorders. These conditions are often intractable and can range in severity from moderate to profound. This article delves into the subject of Slack channel detailing their architecture, physiological functions, distribution, and expression patterns, as well as their essential role in the nervous system. Additionally, we address the topic of epilepsy resulting from mutations in the KCNT1 gene and the therapeutic strategies currently available for managing these challenging conditions.
- 2 March 2026
- Published by Springer Nature in Acta Epileptologica
- Vol. 8 (1)
Open AccessUnraveling the mechanisms of slack channel mutations in epileptic disorders
Sodium-activated potassium channels (K Na ) are extensively expressed throughout the central nervous system (CNS) and play a pivotal role in modulating neuronal excitability. The K Na achieve this by regulating the threshold for action potential initiation and the magnitude of post-hyperpolarization. The KCNT1 gene encodes the α subunit of K Na , also known as Slack channel, is crucial for governing the membrane excitability of neurons. Mutations in the KCNT1 gene impair the function of these potassium channels, leading to seizures and a spectrum of epileptic disorders. These conditions are often intractable and can range in severity from moderate to profound. This article delves into the subject of Slack channel detailing their architecture, physiological functions, distribution, and expression patterns, as well as their essential role in the nervous system. Additionally, we address the topic of epilepsy resulting from mutations in the KCNT1 gene and the therapeutic strategies currently available for managing these challenging conditions.
- Open Access
- 3 January 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Microbiota-derived IPA mitigates post-stroke neuroinflammation by inhibiting TREM2-dependent pyroptosis
Ischemic stroke remains the leading cause of long-term disability globally, underscoring the urgent need for novel therapeutic strategies. Here, we explore
- 3 January 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Open AccessMicrobiota-derived IPA mitigates post-stroke neuroinflammation by inhibiting TREM2-dependent pyroptosis
Ischemic stroke remains the leading cause of long-term disability globally, underscoring the urgent need for novel therapeutic strategies. Here, we explore
- 26 March 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 996, 177553
Regulation of blood-brain barrier integrity by brain microvascular endothelial cells in ischemic stroke: A therapeutic opportunity
- 26 March 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 996, 177553
Regulation of blood-brain barrier integrity by brain microvascular endothelial cells in ischemic stroke: A therapeutic opportunity
- 8 March 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 997, 177482
Physiological implications of the Slack channel in the central and peripheral nervous systems
- 8 March 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 997, 177482
Physiological implications of the Slack channel in the central and peripheral nervous systems
- Open Access
- 24 January 2025
- Published by Wiley in Advanced Science
- Vol. 12 (11) , e2412667
3‐HKA Promotes Vascular Remodeling After Stroke by Modulating the Activation of A1/A2 Reactive Astrocytes
Ischemic stroke is the most common cerebrovascular disease and the leading cause of permanent disability worldwide. Recent studies have shown that stroke development and prognosis are closely related to abnormal tryptophan metabolism. Here, significant downregulation of 3‐hydroxy‐kynurenamine (3‐HKA) in stroke patients and animal models is identified. Supplementation with 3‐HKA improved long‐term neurological recovery, reduced infarct volume, and increased ipsilateral cerebral blood flow after distal middle cerebral artery occlusion (MCAO). 3‐HKA promoted angiogenesis, functional blood vessel formation, and blood‐brain barrier (BBB) repair. Moreover, 3‐HKA inhibited A1‐like (neurotoxic) astrocyte activation but promoted A2‐like (neuroprotective) astrocyte polarization. Proteomic analysis revealed that 3‐HKA inhibited AIM2 inflammasome activation after stroke, and co‐labeling studies indicated that AIM2 expression typically increased in astrocytes at 7 and 14 days after stroke. Consistently, in co‐cultures of primary mouse brain microvascular endothelial cells and astrocytes, 3‐HKA promoted angiogenesis after oxygen‐glucose deprivation (OGD). AIM2 overexpression in astrocytes abrogated 3‐HKA‐driven vascular remodeling in vitro and in vivo, suggesting that 3‐HKA may regulate astrocyte‐mediated vascular remodeling by impeding AIM2 inflammasome activation. In conclusion, 3‐HKA may promote post‐stroke vascular remodeling by regulating A1/A2 astrocyte activation, thereby improving long‐term neurological recovery, suggesting that supplementation with 3‐HKA may be an efficient therapy for stroke.
- 24 January 2025
- Published by Wiley in Advanced Science
- Vol. 12 (11) , e2412667
Open Access3‐HKA Promotes Vascular Remodeling After Stroke by Modulating the Activation of A1/A2 Reactive Astrocytes
Ischemic stroke is the most common cerebrovascular disease and the leading cause of permanent disability worldwide. Recent studies have shown that stroke development and prognosis are closely related to abnormal tryptophan metabolism. Here, significant downregulation of 3‐hydroxy‐kynurenamine (3‐HKA) in stroke patients and animal models is identified. Supplementation with 3‐HKA improved long‐term neurological recovery, reduced infarct volume, and increased ipsilateral cerebral blood flow after distal middle cerebral artery occlusion (MCAO). 3‐HKA promoted angiogenesis, functional blood vessel formation, and blood‐brain barrier (BBB) repair. Moreover, 3‐HKA inhibited A1‐like (neurotoxic) astrocyte activation but promoted A2‐like (neuroprotective) astrocyte polarization. Proteomic analysis revealed that 3‐HKA inhibited AIM2 inflammasome activation after stroke, and co‐labeling studies indicated that AIM2 expression typically increased in astrocytes at 7 and 14 days after stroke. Consistently, in co‐cultures of primary mouse brain microvascular endothelial cells and astrocytes, 3‐HKA promoted angiogenesis after oxygen‐glucose deprivation (OGD). AIM2 overexpression in astrocytes abrogated 3‐HKA‐driven vascular remodeling in vitro and in vivo, suggesting that 3‐HKA may regulate astrocyte‐mediated vascular remodeling by impeding AIM2 inflammasome activation. In conclusion, 3‐HKA may promote post‐stroke vascular remodeling by regulating A1/A2 astrocyte activation, thereby improving long‐term neurological recovery, suggesting that supplementation with 3‐HKA may be an efficient therapy for stroke.
- 4 January 2025
- Published by Elsevier in Life Sciences
- Vol. 362, 123362
Advances in research on metabolic dysfunction-associated steatotic liver disease
- 4 January 2025
- Published by Elsevier in Life Sciences
- Vol. 362, 123362
Advances in research on metabolic dysfunction-associated steatotic liver disease
- Open Access
- 15 February 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (2) , e14596
Inhibiting acid‐sensing ion channel exerts neuroprotective effects in experimental epilepsy via suppressing ferroptosis
Background: Epilepsy is a chronic neurological disease characterized by repeated and unprovoked epileptic seizures. Developing disease‐modifying therapies (DMTs) has become important in epilepsy studies. Notably, focusing on iron metabolism and ferroptosis might be a strategy of DMTs for epilepsy. Blocking the acid‐sensing ion channel 1a (ASIC1a) has been reported to protect the brain from ischemic injury by reducing the toxicity of [Ca 2+ ] i . However, whether inhibiting ASIC1a could exert neuroprotective effects and become a novel target for DMTs, such as rescuing the ferroptosis following epilepsy, remains unknown. Methods: In our study, we explored the changes in ferroptosis‐related indices, including glutathione peroxidase (GPx) enzyme activity and levels of glutathione (GSH), iron accumulation, lipid degradation products‐malonaldehyde (MDA) and 4‐hydroxynonenal (4‐HNE) by collecting peripheral blood samples from adult patients with epilepsy. Meanwhile, we observed alterations in ASIC1a protein expression and mitochondrial microstructure in the epileptogenic foci of patients with drug‐resistant epilepsy. Next, we accessed the expression and function changes of ASIC1a and measured the ferroptosis‐related indices in the in vitro 0‐Mg 2+ model of epilepsy with primary cultured neurons. Subsequently, we examined whether blocking ASIC1a could play a neuroprotective role by inhibiting ferroptosis in epileptic neurons. Results: Our study first reported significant changes in ferroptosis‐related indices, including reduced GPx enzyme activity, decreased levels of GSH, iron accumulation, elevated MDA and 4‐HNE, and representative mitochondrial crinkling in adult patients with epilepsy, especially in epileptogenic foci. Furthermore, we found that inhibiting ASIC1a could produce an inhibitory effect similar to ferroptosis inhibitor Fer‐1, alleviate oxidative stress response, and decrease [Ca 2+ ] i overload by inhibiting the overexpressed ASIC1a in the in vitro epilepsy model induced by 0‐Mg 2+ . Conclusion: Inhibiting ASIC1a has potent neuroprotective effects via alleviating [Ca 2+ ] i overload and regulating ferroptosis on the models of epilepsy and may act as a promising intervention in DMTs.
- 15 February 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (2) , e14596
Open AccessInhibiting acid‐sensing ion channel exerts neuroprotective effects in experimental epilepsy via suppressing ferroptosis
Background: Epilepsy is a chronic neurological disease characterized by repeated and unprovoked epileptic seizures. Developing disease‐modifying therapies (DMTs) has become important in epilepsy studies. Notably, focusing on iron metabolism and ferroptosis might be a strategy of DMTs for epilepsy. Blocking the acid‐sensing ion channel 1a (ASIC1a) has been reported to protect the brain from ischemic injury by reducing the toxicity of [Ca 2+ ] i . However, whether inhibiting ASIC1a could exert neuroprotective effects and become a novel target for DMTs, such as rescuing the ferroptosis following epilepsy, remains unknown. Methods: In our study, we explored the changes in ferroptosis‐related indices, including glutathione peroxidase (GPx) enzyme activity and levels of glutathione (GSH), iron accumulation, lipid degradation products‐malonaldehyde (MDA) and 4‐hydroxynonenal (4‐HNE) by collecting peripheral blood samples from adult patients with epilepsy. Meanwhile, we observed alterations in ASIC1a protein expression and mitochondrial microstructure in the epileptogenic foci of patients with drug‐resistant epilepsy. Next, we accessed the expression and function changes of ASIC1a and measured the ferroptosis‐related indices in the in vitro 0‐Mg 2+ model of epilepsy with primary cultured neurons. Subsequently, we examined whether blocking ASIC1a could play a neuroprotective role by inhibiting ferroptosis in epileptic neurons. Results: Our study first reported significant changes in ferroptosis‐related indices, including reduced GPx enzyme activity, decreased levels of GSH, iron accumulation, elevated MDA and 4‐HNE, and representative mitochondrial crinkling in adult patients with epilepsy, especially in epileptogenic foci. Furthermore, we found that inhibiting ASIC1a could produce an inhibitory effect similar to ferroptosis inhibitor Fer‐1, alleviate oxidative stress response, and decrease [Ca 2+ ] i overload by inhibiting the overexpressed ASIC1a in the in vitro epilepsy model induced by 0‐Mg 2+ . Conclusion: Inhibiting ASIC1a has potent neuroprotective effects via alleviating [Ca 2+ ] i overload and regulating ferroptosis on the models of epilepsy and may act as a promising intervention in DMTs.
- Open Access
- 30 January 2024
- Published by S. Karger AG in Pharmacology
- Vol. 109 (2) , 76-85
Recent Advances in the Therapeutic Potential of Sinomenine for Cancer Treatment
Background: Cancer is a major cause of death worldwide. Although modern medicine has made strides in treatment, a complete cure for cancer remains elusive. Summary: Utilization of medicinal plants in traditional medicine for the treatment of multiple diseases, including cancer, is a well-established practice. Sinomenine is an alkaloid extracted from a medicinal plant and has a diverse range of biological properties, including anti-oxidative, anti-inflammatory, and antibacterial effects. Sinomenine exhibits inhibitory effects on various types of tumor cells, including breast, lung, and liver cancers. The anticancer properties of sinomenine are believed to involve stimulation of apoptosis and autophagy as well as suppression of cell proliferation, invasion, and metastasis. Key Message: This review summarizes the current research on sinomenine’s potential as an anticancer agent, which may contribute to the discovery of more effective cancer treatments.
- 30 January 2024
- Published by S. Karger AG in Pharmacology
- Vol. 109 (2) , 76-85
Open AccessRecent Advances in the Therapeutic Potential of Sinomenine for Cancer Treatment
Background: Cancer is a major cause of death worldwide. Although modern medicine has made strides in treatment, a complete cure for cancer remains elusive. Summary: Utilization of medicinal plants in traditional medicine for the treatment of multiple diseases, including cancer, is a well-established practice. Sinomenine is an alkaloid extracted from a medicinal plant and has a diverse range of biological properties, including anti-oxidative, anti-inflammatory, and antibacterial effects. Sinomenine exhibits inhibitory effects on various types of tumor cells, including breast, lung, and liver cancers. The anticancer properties of sinomenine are believed to involve stimulation of apoptosis and autophagy as well as suppression of cell proliferation, invasion, and metastasis. Key Message: This review summarizes the current research on sinomenine’s potential as an anticancer agent, which may contribute to the discovery of more effective cancer treatments.